| ²é¿´: 486 | »Ø¸´: 2 | ||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
xiaowanzi9гæ (ÕýʽдÊÖ)
|
[ÇóÖú]
ÇóÖúÒ»¶Î·Òë¡£Á¿´ó
|
|
|
Finally, we investigated direct effects of fumaric acid esters on the inhibitor of Nrf2, Keap1 in vitro. Mass spectroscopy revealed a covalent modification at the cysteine residue 151 of the Keap1 protein after monomethylfumarate treatment (Fig. 5G). The matched Keap1 peptides (peptide score 47) from a SpectrumMill database search covered 95% of the rat Keap1 protein sequence. After stimulation with monomethylfumarate, a 130 Da mass increase of the Keap1 tryptic peptide CVLHVMNGAVMYQIDSVVR was observed. The mass increase of 130 Da is consistent with a Michael addition of a free cysteine sulphydryl group across the monomethylfumarate double bond. The MS/MS spectrum of the peptide confirms this modification at cysteine 151 (Fig. 5G). The assignment of 130 Da to the monomethylfumarate modification is consistent (within 0.14 mmu) with a chemical formula of C5H6O4 (130.02661 exp. and 130.02647 cal.). The ion intensity ratio of the modified and unmodified peptides are 69 and 31%, respectively. The monomethylfumarate induced 130 Da modification was also observed¨C¨Cto a much lower extent¨C¨Cin other cysteine-containing Keap1 peptides (Table 2). |
» ²ÂÄãϲ»¶
292Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
11408 Ò»Ö¾Ô¸Î÷µç£¬277·ÖÇóµ÷¼Á
ÒѾÓÐ3È˻ظ´
²ÄÁÏ295
ÒѾÓÐ13È˻ظ´
085600²ÄÁÏÓ뻯¹¤µ÷¼Á
ÒѾÓÐ24È˻ظ´
316Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Ò»Ö¾Ô¸±±½»´ó²ÄÁϹ¤³Ì×Ü·Ö358
ÒѾÓÐ4È˻ظ´
081700»¯Ñ§¹¤³ÌÓë¼¼Êõ Ò»Ö¾Ô¸Öк£Ñó 323 Çóµ÷¼ÁѧУ
ÒѾÓÐ10È˻ظ´
387Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸¹þ¶û±õ¹¤Òµ´óѧ085600Ó¢Ò»Êý¶þ337·ÖÇóµ÷¼Á
ÒѾÓÐ6È˻ظ´
085600£¬320·ÖÇóµ÷¼Á
ÒѾÓÐ6È˻ظ´

genhunter
ÖÁ×ðľ³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 387
- Ó¦Öú: 259 (´óѧÉú)
- ½ð±Ò: 9757.4
- É¢½ð: 10
- ºì»¨: 60
- Ìû×Ó: 2484
- ÔÚÏß: 1793Сʱ
- ³æºÅ: 2558361
- ×¢²á: 2013-07-22
- רҵ: Ö×Áö»¯Ñ§Ò©ÎïÖÎÁÆ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
xiaowanzi9: ½ð±Ò+20 2015-05-25 16:26:12
xiaowanzi9: ½ð±Ò+20 2015-05-25 16:26:12
| ×îºó£¬ÎÒÃÇÑо¿ÁËÌåÍâ·´¶¡Ï©¶þËáÖ¬¶ÔNrf2ÒÖÖ¹ÎïKeap1µÄÖ±½Ó×÷ÓÃ(»òЧӦ). ÖÊÆ×ÏÔʾKeap1λÓÚ151µÄ°ëë×°±ËáÉϵÄÛÏ»ùÔÚ·´¶¡Ï©¶þËáµ¥¼×Ö¬´¦Àíºó±»¹²¼ÛÐÞÊÎÁË(ͼ 5G)¡£Í¨¹ý´ÓSpectrum MillÊý¾Ý¿âÖи²¸Ç95%´óÊóKeap1µ°°×˳Ðò¼ìË÷ÕÒµ½Á˼¸¸ö¶àëÄÆ¬¶Î(¶àëÄͬԴֵΪ47)¡£Í¨¹ýÓ÷´¶¡Ï©¶þËáµ¥¼×֬ģÄ⣬Keap1ÒÈø½µ½â¶àëÄÆ¬¶ÎCVLHVMNGAVMYQIDSVVR·Ö×ÓÁ¿»áÔö¼Ó130 Da. ·Ö×ÓÁ¿Ôö¼Ó130 DaÊÇÓÉÓÚÒ»¸öÓÎÀëÛÏ»ùÓë·´¶¡Ï©¶þËáµ¥¼×֬˫¼üͨ¹ýÂõ¿Ë¶û¼Ó³ÉºóÐγɵġ£. MS/MSͼÆ×È·ÈÏÐÞÊÎλÓÚλÓÚ151µÄ°ëë×°±ËáÉÏ. ·Ö×ÓÁ¿Ôö¼Ó130 DaÍÆËã³ö·´¶¡Ï©¶þËáµ¥¼×Ö¬»ùÍÅÓëÆä»¯Ñ§Ê½C5H6O4ÏàÎǺÏ(¾«È·µ½0.14mmu, ʵ²â130.02661 £¬ÀíÂÛÖµ 130.02647)¡£¾ÐÞÊκÍδ¾ÐÞÊεĶàëÄÀë×Ó·åÖµ±ÈÀý·Ö±ðÊÇ69ºÍ31%¡£·´¶¡Ï©¶þËáµ¥¼×Ö¬Ò²µ¼ÖÂͬÑù130 DaÐÞÊÎÔÚÆäËûº¬°ëë×°±ËáµÄKeap1¶àëÄÆ¬¶ÎÖÐÒ²¿É¹Û²ìµ½£¬µ«º¬Á¿ÒªµÍºÜ¶à¡£(±í¶þ) |

2Â¥2015-05-25 15:50:31
Î人һÐÄÒ»Òë
¾èÖú¹ó±ö (ÖøÃûдÊÖ)
- ·ÒëEPI: 502
- Ó¦Öú: 8 (Ó×¶ùÔ°)
- ½ð±Ò: 2283.1
- É¢½ð: 5914
- ºì»¨: 32
- Ìû×Ó: 1665
- ÔÚÏß: 321.9Сʱ
- ³æºÅ: 3587652
- ×¢²á: 2014-12-10
- ÐÔ±ð: GG
- רҵ: ¸ß·Ö×Ӻϳɻ¯Ñ§
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
É̼ÒÒѾÖ÷¶¯ÉùÃ÷´Ë»ØÌû¿ÉÄܺ¬ÓÐÐû´«ÄÚÈÝ
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
xiaowanzi9: ½ð±Ò+30, ·ÒëEPI+1 2015-05-25 16:26:09
xiaowanzi9: ½ð±Ò+30, ·ÒëEPI+1 2015-05-25 16:26:09
|
Finally, we investigated direct effects of fumaric acid esters on theinhibitor of Nrf2, Keap1 in vitro. ×îºó£¬ÎÒÃÇÑо¿ÁË ·´¶¡Ï©¶þËáËáõ¥¶ÔKeap1ÌåÍ⣬Nrf2µÄÒÖÖÆ¼ÁµÄÖ±½Ó×÷Óà Mass spectroscopy revealed a covalent modification at the cysteineresidue 151 of the Keap1 protein after monomethylfumarate treatment (Fig. 5G). The matched Keap1 peptides (peptide score 47) from a Spectrum Mill database search covered 95% of the rat Keap1 protein sequence. ÖÊÆ×·ÖÎö±íÃ÷£¬ ÔËÓø»ÂíËáµ¥¼×õ¥½øÐд¦Àíºó£¬»áÐγÉÒ»ÖÖ£¬¶ÔKeap1µ°°×Öʵİëë×°±Ëá²Ð»ù151µÄ¹²¼ÛÐÞÊΣ¨Èçͼ5G£©¡£Í¨¹ý¹âÆ×Êý¾Ý¿âËÑË÷»ñµÃµÄÓë֮ƥÅäµÄKeap1¶àëÄ£¨ëÄ·ÖΪ47£©£¬ ¸²¸ÇÁË95%µÄÀÏÊóKeap1µ°°×ÖÊÐòÁС£ After stimulation with monomethylfumarate,a 130 Da mass increase of the Keap1 tryptic peptide CVLHVMNGAVMYQIDSVVR was observed. The mass increase of 130 Da is consistent with a Michael addition of a free cysteine sulphydryl group across the monomethylfumarate double bond. ÔËÓø»ÂíËáµ¥¼×õ¥½øÐд̼¤ºó£¬¿ÉÒԹ۲쵽£¬Keap1Òȵ°°×øëÄ£¬»á²úÉú130 Da¼¶µÄÖÊÁ¿Ôö¼Ó¡£¸Ã130DaµÄÖÊÁ¿Ôö¼Ó£¬Óë×ÔÓɰëë×°±ËáÛÏ»ù¼¯ÍÅÔÓ½»¸»ÂíËáµ¥¼×õ¥Ë«¼ü£¬µÄÂõ¿Ë¶û¼Ó³É·´Ó¦Ò»Ö¡£ The MS/MS spectrum of the peptide confirms this modification at cysteine 151 (Fig. 5G). The assignment of 130 Da to the monomethylfumarate modification is consistent (within 0.14 mmu) with a chemical formula of C5H6O4 (130.02661 exp. and 130.02647 cal.). The ion intensity ratio of the modified and unmodified peptides are 69 and 31%, respectively. Ëõ°±ËáµÄ´®ÁªÊ½ÖÊÆ×·¨£¬È·¶¨Á˰ëë×°±Ëá151£¨Èçͼ5G£© ÐÞÊΡ£130 Da·ÖÅäµ½¸»ÂíËáµ¥¼×õ¥ÐÞÊΣ¬Ó루ÔÚ0.14 mmuÄڵģ©C5H6O4µÄ»¯Ñ§Ê½ £¨130.02661 exp. and 130.02647 cal.£©Ò»Ö¡£ÐÞÊÎ/δÐÞÊεÄëĵÄÏà¶ÔÀë×ÓÇ¿¶È±È·Ö±ðΪ69% ºÍ 31%¡£ The monomethylfumarate induced 130 Da modification was also observed¨C¨Cto a much lower extent¨C¨Cin other cysteine-containing Keap1 peptides (Table 2). ͬʱ£¬Ò²¿ÉÒԹ۲쵽¸»ÂíËáµ¥¼×õ¥Óз¨µÄ130 DaµÄÐÞÊΡ£ÔÚº¬ÆäËü°ëë×°±ËáµÄKeap1¶àëÄÖУ¬ÆäÐÞÊγ̶ȸüµÍ¡££¨Èç±í¶þËùʾ£© |
3Â¥2015-05-25 15:54:36














»Ø¸´´ËÂ¥
10